Literature DB >> 6942183

Potentiation of anticancer agents by amphotericin B.

G Medoff, F Valeriote, J Dieckman.   

Abstract

Amphotericin B (AmB) has been shown to potentiate the cytotoxicity of several different anticancer agents in AKR mice. The extent of potentiation, as assessed quantitatively by a spleen colony assay, varied from a factor of approximately 3 for 1,3-bis(2-chlorethyl)-1-nitrosourea (BCNU) to over 100 for a number of alkylating agents and to over 1,000 for 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Most phase-specific agents showed little potentiation of cytotoxicity by AmB. A dose-response effect was noted with both BCNU and adriamycin, with increased potentiation being observed with increasing doses of the anticancer agents. The effect on increase in life-span was also studied and for most of the combinations it correlated with the potentiating effects disclosed by the spleen colony assay. Such a correlation was not found for AmB combined with either BCNU or vincristine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6942183

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

1.  Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B.

Authors:  S S Cao; Y S Zhen
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.

Authors:  A Adedoyin; J F Bernardo; C E Swenson; L E Bolsack; G Horwith; S DeWit; E Kelly; J Klasterksy; J P Sculier; D DeValeriola; E Anaissie; G Lopez-Berestein; A Llanos-Cuentas; A Boyle; R A Branch
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

3.  Potentiation by amphotericin B of the cytotoxicity of anticancer agents against MOPC-315 plasmacytoma and Lewis lung carcinoma.

Authors:  F Valeriote; J Dieckman; D Flentje; M Flentje; G Medoff
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.

Authors:  S Y Sharp; P Mistry; M R Valenti; A P Bryant; L R Kelland
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line.

Authors:  T Morikage; M Bungo; M Inomata; M Yoshida; T Ohmori; Y Fujiwara; K Nishio; N Saijo
Journal:  Jpn J Cancer Res       Date:  1991-06

6.  pH regulation of amphotericin B channels activity in the bilayer lipid membrane.

Authors:  Tahereh Shahmoradi; Hamid Sepehry; Manuchehr Ashrafpour
Journal:  J Nat Sci Biol Med       Date:  2016 Jan-Jun

7.  Potentiation of cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) by amphotericin B in BALB/c nude mice bearing human ovarian carcinoma cells.

Authors:  M Kojima; F Kikkawa; H Oguchi; K Tamakoshi; O Maeda; N Suganuma; Y Tomoda
Journal:  Jpn J Cancer Res       Date:  1994-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.